--- title: "PACE Interim Impact Report" ocid: "ocds-h6vhtk-05f160" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f160" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-05f160.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-05f160.json" source: "Find A Tender Service" current_stage: "Tender" buyer: "MEDICINES DISCOVERY CATAPULT LIMITED" published: "2025-12-09" --- # PACE Interim Impact Report Buyer: MEDICINES DISCOVERY CATAPULT LIMITED Current stage: Tender OCID: ocds-h6vhtk-05f160 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f160) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-05f160.json) ## Summary The Medicines Discovery Catapult Limited, a sub-central government public authority located in Macclesfield, UK, is seeking an external provider to conduct an interim impact review for the PACE (Pathways to Antimicrobial Clinical Efficacy) programme. This procurement is aimed at producing an interim report evaluating the progress and impact of PACE activities, which underpin a £30 million initiative supporting early-stage innovation in the field of antimicrobial drugs and diagnostics. The tender, titled "PACE Interim Impact Report," is open for electronic submissions until 9 January 2026. It involves business and management consultancy services within the UK region, with a total contract value standing at £50,000. The tender process is open and below threshold, with quality being the predominant award criterion. This tender presents significant opportunities for businesses within the consultancy sector, particularly those specialising in impact evaluation and antimicrobial research support. SMEs with expertise in producing analytical reports and evaluations for public health initiatives will find this contract highly fitting. Successful engagement could lead to further collaborations and increased visibility within public sector projects tackling vital healthcare challenges such as antimicrobial resistance. The opportunity to network with leading health innovation bodies like Innovate UK and LifeArc, as part of this project's potential future developments, also stands to boost the business growth for the winning bidder. ## Notice PACE (Pathways to Antimicrobial Clinical Efficacy) is a PS30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. PACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery: Grow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact. Provide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets Convene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D. It is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline. The PACE programme is funded for an initial term of five years and as of April 2026 will reach its midway point in this funding cycle and so there is a need to conduct an interim review of progress towards expected outcomes. Findings from this interim review will directly inform programme refinement. Key to this will be the opportunity to gather feedback and learning from Round 1 beneficiaries and partners on the PACE Academy, the project management process, and the use of Enabling projects so far. It will also allow the programme to capture the experiences of beneficiaries from Round 2 to date. This will provide learning in how best to support the Round 2 beneficiaries and for the future Round 3 of funding which will be targeted at a second group of therapeutic companies. It is expected that findings from the interim review will directly inform the need and shape for PACE beyond the first 5 - year funded term. The PACE programme is now looking for an external provider to develop and produce an interim impact review and report (that will build upon the existing baseline impact study completed in June 2025) to understand how key activities are progressing towards expected outcomes which can be compared to the findings from the baseline study and at the endline stage. The overall purpose of the impact evaluation and this interim review is to be able to assess the impact of PACE on the AMR drug development ecosystem and on the development of drugs and diagnostics. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/080894-2025 | | Notice type | UK4 - Tender Notice | | Procurement type | Standard | | Procurement category | Services | | Procurement method | Open | | Procurement method details | Below threshold - open competition | | Tender suitability | SME | | Awardee scale | Not specified | | All stages | Tender | ## Dates | Field | Value | | --- | --- | | Publication date | 9 Dec 2025 | | Submission deadline | 9 Jan 2026 | | Future notice date | Not specified | | Award date | Not specified | | Contract period | 2 Feb 2026 - 31 Jul 2026 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £50,000 | | Lots value | £50,000 | | Awards value | Not specified | | Contracts value | Not specified | ## Status | Field | Value | | --- | --- | | Tender status | Active | | Lots status | Active | | Awards status | Not specified | | Contracts status | Not specified | ## Buyer | Field | Value | | --- | --- | | Main buyer | MEDICINES DISCOVERY CATAPULT LIMITED | | Locality | MACCLESFIELD | | Post town | Stockport | | Postcode | SK10 4ZF | | Country | England | | ITL 1 | TLD North West (England) | | ITL 2 | TLD6 Cheshire | | ITL 3 | TLD62 Cheshire East | | Local authority | Cheshire East | | Electoral ward | Chelford | | Westminster constituency | Tatton | | Delivery location | Not specified | ## CPV Codes ### Divisions - 79 - Business services: law, marketing, consulting, recruitment, printing and security ### Codes - 79410000 - Business and management consultancy services ## Release History - 9 Dec 2025 at 09:26 - TenderUpdate - UK4 - Tender Notice - https://www.find-tender.service.gov.uk/Notice/080894-2025 - 9 Dec 2025 at 09:20 - Tender - UK4 - Tender Notice - https://www.find-tender.service.gov.uk/Notice/080889-2025 ## Documents - https://www.find-tender.service.gov.uk/Notice/080894-2025 9th December 2025 - Tender notice on Find a Tender - https://www.find-tender.service.gov.uk/Notice/080889-2025 9th December 2025 - Tender notice on Find a Tender ## Notice URLs - https://procontract.due-north.com/Advert/?advertId=37a0881b-dfd4-f011-813a-005056b64545 - https://www.legislation.gov.uk/ukpga/2023/54/contents ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-05f160. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-05f160.json.